200 related articles for article (PubMed ID: 23404201)
41. [Therapy of glucocorticoid induced osteoporosis].
Arazzi M; Di Fulvio G; Di Pietro LO; Grabocka X; Longo MO; Micioni G; Pezzutto A; Piscitani L; Schiazza A; Silvestri S; Vigilante G; Amoroso L; Bonomini M
G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207221
[TBL] [Abstract][Full Text] [Related]
42. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.
Devogelaer JP; Goemaere S; Boonen S; Body JJ; Kaufman JM; Reginster JY; Rozenberg S; Boutsen Y
Osteoporos Int; 2006 Jan; 17(1):8-19. PubMed ID: 16217586
[TBL] [Abstract][Full Text] [Related]
43. Management of glucocorticoid-induced osteoporosis in male veterans.
Elliott ME; Farrah RM; Binkley NC; Carnes ML; Gudmundsson A
Ann Pharmacother; 2000 Dec; 34(12):1380-4. PubMed ID: 11144692
[TBL] [Abstract][Full Text] [Related]
44. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
45. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
46. Glucocorticoid-induced osteoporosis in patients with sarcoidosis.
Adler RA; Funkhouser HL; Petkov VI; Berger MM
Am J Med Sci; 2003 Jan; 325(1):1-6. PubMed ID: 12544077
[TBL] [Abstract][Full Text] [Related]
47. Vitamin D supplementation in a healthy, middle-aged population: actual practices based on data from a French comprehensive regional health-care database.
Caillet P; Souberbielle JC; Jaglal SB; Reymondier A; Van Ganse E; Chapurlat R; Schott AM
Eur J Clin Nutr; 2013 Nov; 67(11):1133-7. PubMed ID: 24084513
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
49. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J
Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716
[TBL] [Abstract][Full Text] [Related]
50. Determinants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners.
Buckinx F; Reginster JY; Cavalier E; Petermans J; Ricour C; Dardenne C; Bruyère O
Osteoporos Int; 2016 Mar; 27(3):881-886. PubMed ID: 26733374
[TBL] [Abstract][Full Text] [Related]
51. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
De Nijs RN
Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
[TBL] [Abstract][Full Text] [Related]
52. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
Boling EP
Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
[TBL] [Abstract][Full Text] [Related]
53. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents.
Brown JJ; Zacharin MR
J Paediatr Child Health; 2005 Nov; 41(11):580-2. PubMed ID: 16398842
[TBL] [Abstract][Full Text] [Related]
54. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.
Curtis JR; Westfall AO; Allison JJ; Becker A; Casebeer L; Freeman A; Spettell CM; Weissman NW; Wilke S; Saag KG
Arthritis Rheum; 2005 Aug; 52(8):2485-94. PubMed ID: 16052570
[TBL] [Abstract][Full Text] [Related]
55. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia.
Bijlsma JW; Raymakers JA; Mosch C; Hoekstra A; Derksen RH; Baart de la Faille H; Duursma SA
Clin Exp Rheumatol; 1988; 6(2):113-9. PubMed ID: 3180536
[TBL] [Abstract][Full Text] [Related]
56. Glucocorticoid-induced osteoporosis in inflammatory bowel disease.
Lidofsky S; Smith J
Med Health R I; 2009 Apr; 92(4):128-30. PubMed ID: 19452756
[TBL] [Abstract][Full Text] [Related]
57. Underutilization of calcium and vitamin D supplements in an academic long-term care facility.
Kamel HK
J Am Med Dir Assoc; 2004; 5(2):98-100. PubMed ID: 14984620
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.
Gudbjornsson B; Juliusson UI; Gudjonsson FV
Ann Rheum Dis; 2002 Jan; 61(1):32-6. PubMed ID: 11779755
[TBL] [Abstract][Full Text] [Related]
59. Vitamin D therapy.
Geller JL; Adams JS
Curr Osteoporos Rep; 2008 Mar; 6(1):5-11. PubMed ID: 18430394
[TBL] [Abstract][Full Text] [Related]
60. Glucocorticoid-induced osteoporosis and its treatment.
Pennisi P; Trombetti A; Rizzoli R
Clin Orthop Relat Res; 2006 Feb; 443():39-47. PubMed ID: 16462424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
